Table 3 Renal cell arrest and damage markers and urine sediment scores in study patients
| Â | Total | Progression | p | |
|---|---|---|---|---|
No | Yes | |||
IGFBP-7 × TIMP-2 (ng/ml)2/1000) | 0.48 (0.33–0.75) | 0.34 (0.16–0.46) | 0.66 (0.49–2.17) | < 0.001* |
KIM-1 (pg/ml) | 1310 (1070–1545) | 1235 (875–1505) | 1437.5 (1150–1690) | 0.008* |
P1 | (n = 96) | (n = 50) | (n = 46) |  |
 0 | 27 (28.1%) | 16 (32.0%) | 11 (23.9%) | 0.125 |
 1 | 44 (45.8%) | 26 (52.0%) | 18 (39.1%) | |
 2 | 22 (22.9%) | 7 (14.0%) | 15 (32.6%) | |
 3 or more | 3 (3.1%) | 1 (2.0%) | 2 (4.3%) | |
P2 | (n = 96) | (n = 50) | (n = 46) |  |
 0 | 17 (17.7%) | 17 (34.0%) | 0 (0.0%) | < 0.001* |
 1 | 22 (22.9%) | 19 (38.0%) | 3 (6.5%) | |
 2 | 27 (28.1%) | 11 (22.0%) | 16 (34.8%) | |
 3 or more | 30 (31.3%) | 3 (6.0%) | 27 (58.7%) | |
P3 | (n = 70) | (n = 35) | (n = 35) |  |
 0 | 19 (27.1%) | 18 (51.4%) | 1 (2.9%) | < 0.001* |
 1 | 12 (17.1%) | 11 (31.4%) | 1 (2.9%) | |
 2 | 14 (20.0%) | 5 (14.3%) | 9 (25.7%) | |
 3 or more | 25 (35.7%) | 1 (2.9%) | 24 (68.6%) | |
C1 | (n = 96) | (n = 50) | (n = 46) |  |
 1 | 47 (49.0%) | 31 (62.0%) | 16 (34.8%) | 0.018* |
 2 | 47 (49.0%) | 18 (36.0%) | 29 (63.0%) | |
 3 or more | 2 (2.1%) | 1 (2.0%) | 1 (2.2%) | |
C2 | (n = 96) | (n = 50) | (n = 46) |  |
 1 | 34 (35.4%) | 33 (66.0%) | 1 (2.2%) | < 0.001* |
 2 | 31 (32.3%) | 16 (32.0%) | 15 (32.6%) | |
 3 or more | 31 (32.3%) | 1 (2.0%) | 30 (65.2%) | |
C3 | (n = 70) | (n = 35) | (n = 35) |  |
 1 | 31 (44.3%) | 30 (85.7%) | 1 (2.9%) | < 0.001* |
 2 | 15 (21.4%) | 4 (11.4%) | 11 (31.4%) | |
 3 or more | 24 (34.3%) | 1 (2.9%) | 23 (65.7%) | |